Rising Prevalence Of Liver Disorders To Propel The Growth Of Global Ascites Market During 2017-2023 :

 Pune, India, October, 2018 /press release/- Market Research Future Published a Half-Cooked Research Report on Ascites Market Research Report.

Market Overview:

Ascites is caused due to abnormal accumulation of fluids in the peritoneal cavity and is mainly triggered by other disorders such as acute liver failure, liver cirrhosis, cancer, pancreatic disorders, heart failure, ovarian diseases, hypothyroidism and others. Market Research Future (MRFR), the global ascites market is anticipated to expand at a steady CAGR of 4% during the forecast period (2017-2023).

Market Drivers and Restraints:

Increasing alcohol abuse, changing lifestyles and other factors are leading to the rise in prevalence of liver cirrhosis which is triggering the incidences of ascites. This rise in ascites incidences is inducing high demand for effective treatments, leading to the significant growth of the global ascites market. Proliferation of cancer patients all over the world and increasing prevalence of diabetes are some other factors that are driving the expansion of the global ascites market.

However, complexities regarding the diagnosis and treatment procedures and low awareness of the disease in the underdeveloped regions are likely to restrain the expansion of the global ascites market during the assessment period.

Segmental Analysis:

The global ascites market has been segmented by type, treatment, diagnosis and end user. Based on type, the ascites market has been segmented into transudative ascites, and exudate ascites. Based on diagnosis, the ascites market has been segmented into ultrasound, CT scan, laparoscopy, angiography, and others.

Based on treatment, the ascites market has been segmented into surgeries and others. The surgeries segment has been sub-segmented into peritoneovenous shunting, liver transplantation, transjugular intrahepatic portosystemic shunt (TIPS), and others. Based on end -users, the ascites market has been segmented into hospital, and clinics, ambulatory surgical centers, diagnostic centers, and others.

Regional Analysis


The global ascites market has been geographically segmented into four major regions such as Europe, Asia Pacific, the Americas and the Middle East and Africa. The Americas are projecting dominance over the global ascites market owing to the high prevalence of liver diseases caused due to increased alcohol consumption and changing lifestyle and easy adoption of advanced treatment methods in the well-developed healthcare infrastructure in this region.

The ascites market in the Europe region is majorly driven by rapid incorporation of advanced technologies in the healthcare sector, high healthcare expenditure and increased government funding for research and development of effective treatments in this region. The Asia Pacific region is growing at fastest rate in the global ascites market due to increasing awareness regarding ascites and its causative factors and inclination of population towards getting proper treatment for the disease. The Middle East and Africa region is anticipated to project steady growth in the global ascites market owing to the poor primary health care facilities and lack of awareness in the underdeveloped countries of this region.

Access Report @ https://www.marketresearchfuture.com/reports/ascites-market-1909

Industry Updates:

In September 2018, Sequana Medical AG, a commercial stage medical device manufacturer, has announced that its device named alfapump® has projected positive findings and is effective in treating palliative patients with malignant ascites and other fluid imbalance disorders.

In June 2018, Clover Biopharmaceuticals, a biotechnology company focused on developing transformative biologic therapies, has announced a successful phase I trial of SCB-313 which is an investigational fully-human TRAIL-trimer fusion protein, used for the treatment of patients with malignant ascites.

In April 2018, BioVie Inc., a clinical-stage company focused on development and commercialization of innovative drug therapies for liver diseases, has announced that it has achieved a significant number of patients enrolling for its open-label Phase 2a clinical study of BIV201 (continuous infusion terlipressin) for the treatment of refractory ascites caused due to advanced liver cirrhosis.

Key Players:

The prominent players that are profiled by MRFR in the report on the global ascites market are Sequana Medical, BioVie, PharmaCyte Biotech Inc., Fresenius SE & Co. KGaA, Medtronic plc, BD, GI Supply, and others.